With 0.8 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.89 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $6.165 whereas the lowest price it dropped to was $5.68. The 52-week range on PSNL shows that it touched its highest point at $7.20 and its lowest point at $1.12 during that stretch. It currently has a 1-year price target of $7.65. Beta for the stock currently stands at 1.80.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PSNL was up-trending over the past week, with a rise of 3.83%, but this was up by 51.91% over a month. Three-month performance surged to 10.97% while six-month performance rose 399.58%. The stock gained 154.04% in the past year, while it has gained 184.29% so far this year. A look at the trailing 12-month EPS for PSNL yields -1.68 with Next year EPS estimates of -1.04. For the next quarter, that number is -0.28. This implies an EPS growth rate of 36.09% for this year and 27.77% for next year. EPS is expected to decline by -13.70% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -28.46%.
Float and Shares Shorts:
At present, 70.64 million PSNL shares are outstanding with a float of 35.14 million shares on hand for trading. On 2024-12-13, short shares totaled 2.97 million, which was 421.0 higher than short shares on 1731628800. In addition to Mr. Christopher M. Hall as the firm’s President, CEO & Director, Mr. Aaron L. Tachibana serves as its CFO & COO.
Institutional Ownership:
Through their ownership of 0.44356 of PSNL’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, PSNL reported revenue of $25709000.0 and operating income of -$14382000.0. The EBITDA in the recently reported quarter was -$36321000.0 and diluted EPS was -$0.64.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PSNL since 13 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 7 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With PSNL analysts setting a high price target of 10.67 and a low target of 5.0, the average target price over the next 12 months is 7.584. Based on these targets, PSNL could surge 78.73% to reach the target high and fall by -16.25% to reach the target low. Reaching the average price target will result in a growth of 27.04% from current levels.
Analysts have provided yearly estimates in a range of -$1.35401 being high and -$1.51145 being low. For PSNL, this leads to a yearly average estimate of -$1.43798. Based on analyst estimates, the high estimate for the next quarter is -$0.17 and the low estimate is -$0.33. The average estimate for the next quarter is thus -$0.26.
